Quarterly ResultMay 7, 2026, 04:21 PM
Myomo Q1 Revenue $10.1M, Net Loss Narrows to $(0.07)/Share
AI Summary
Myomo, Inc. reported first quarter 2026 financial results with revenue of $10.1 million, a 3% increase year-over-year. The company narrowed its net loss to $3.0 million, or $(0.07) per share, and improved Adjusted EBITDA by 20%. Key operational achievements include 49% of revenue from recurring patient sources and a 12% increase in MyoPro orders received, alongside expanded market access. The company provided Q2 2026 revenue guidance of $10.3 million to $10.8 million and reaffirmed full-year revenue guidance.
Key Highlights
- Q1 2026 revenue increased 3% year-over-year to $10.1 million.
- Net loss narrowed to $(3.0) million, or $(0.07) per share, from $(3.5) million.
- Adjusted EBITDA improved 20% year-over-year to $(2.3) million.
- 49% of Q1 revenue was from recurring patient sources, up from 25% a year ago.
- MyoPro orders received rose 12% year-over-year to 239 units.
- Gross margin expanded by 100 basis points to 68.2%.
- Q2 2026 revenue guidance is $10.3 million to $10.8 million.
- Full year 2026 revenue guidance reaffirmed at $43 million to $46 million.